Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - cabozantinib (s)-malate, quantity: 76.03 mg (equivalent: cabozantinib, qty 60 mg) - tablet, film coated - excipient ingredients: titanium dioxide; magnesium stearate; hypromellose; triacetin; colloidal anhydrous silica; iron oxide yellow; hyprolose; lactose; croscarmellose sodium; microcrystalline cellulose - renal cell carcinoma (rcc),cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):,- in treatment-na?ve adults with intermediate or poor risk,- in adults following prior treatment with vascular endothelial growth factor targeted therapy.,cabometyx in combination with nivolumab is indicated for the first-line treatment of advanced renal cell carcinoma.,hepatocellular carcinoma (hcc),cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.,differentiated thyroid carcinoma (dtc),cabometyx is indicated as monotherapy for the treatment of adult and paediatric patients aged 12 years and older with locally advanced or metastatic differentiated thyroid carcinoma (dtc) that has progressed during or after prior vegfr-targeted therapy and who are radioactive iodine (rai) refractory or ineligible.

Malta - English - Medicines Authority

ipsen pharma 65 quai georges gorse, 92100 boulogne-billancourt,, france - solution for injection - botulinum toxin type a 125 u/ml - muscle relaxants

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate; water for injections -

Malta - English - Medicines Authority

ipsen m.e.p.e ag. dimitriou 63 alimos, 17456 athens, greece - hexaminolevulinate - powder and solvent for solution for intravesical use - hexaminolevulinate 85 mg - diagnostic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 31 mg (equivalent: triptorelin, qty 22.5 mg) - suspension, powder for - excipient ingredients: polyglactin; carmellose sodium; polysorbate 80; mannitol - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.,diphereline 22.5mg 6 month formulation only:,diphereline 22.5 mg is indicated for the treatment of children 2 years and older with central precocious puberty (cpp).

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 19.32 mg - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - triptorelin embonate, quantity: 5.6 mg (equivalent: triptorelin, qty 3.75 mg) - injection, diluent for - excipient ingredients: water for injections - diphereline is indicated for the treatment of hormone-dependent locally advanced or metastatic prostate cancer.

Australia - English - Department of Health (Therapeutic Goods Administration)

ipsen pty ltd - mecasermin, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; benzyl alcohol; polysorbate 20; glacial acetic acid; sodium acetate trihydrate; water for injections - for the long-term treatment of growth failure in children and adolescents from 2 to 18 years with severe primary insulin-like growth factor 1 deficiency (primary igfd).,severe primary igfd is defined by:,? height standard deviation score less than or equal to ?3.0 and,? baseline height velocity less than the 25th percentile for bone age, based on two measurements over 12 months and,? basal igf-1 levels below the 2.5th percentile for age and gender and,? gh sufficiency.,? exclusion of secondary forms of igf-1 deficiency, such as malnutrition, hypopituitarism, hypothyroidism, or chronic treatment with pharmacologic doses of anti-inflammatory steroids.,igf-1 and gh levels must be performed using validated assays with paediatric normal ranges.

Ireland - English - HPRA (Health Products Regulatory Authority)

thornton & ross limited - piperazine phosphate sennoside b - powder for oral suspension - 4000/15.3m milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

cupal limited - piperazine hydrate - oral solution - 750 mg/5ml